Biohaven (BHVN) Research Hub

Biohaven (BHVN) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 14.45 USD (+4.11%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.60, market cap 1.57B. This hub links to the full technical, earnings and options research available for BHVN.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNYSE, US
Last close14.45 USD (+4.11%)
52-week range10.71 USD – 18.24 USD
Trend regimeRange
14-day RSI64.6 (Bullish)
Trailing P/E-2.60
Market cap1.57B
Dividend yield0.00%
Next earnings2026-08-10

Available research for BHVN

Earnings

BHVN earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E -2.60. Updated 2026-07-23.

Options: Covered Call

Covered Call on BHVN: how it works, illustrative setup around the real 14.45 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on BHVN: how it works, illustrative setup around the real 14.45 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on BHVN: how it works, illustrative setup around the real 14.45 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

BHVN technical analysis: range, last 14.45 USD, RSI 64.6, 52w range 10.71 USD–18.24 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is BHVN in?

Biohaven (BHVN) is classified under Healthcare (Biotechnology), listed on NYSE, US.

Is BHVN in an uptrend or downtrend?

As of 2026-10-26, BHVN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is BHVN's trailing P/E ratio?

BHVN's trailing P/E is -2.60, with a market cap of 1.57B. See the earnings research page for full valuation detail.

When does BHVN next report earnings?

BHVN is next scheduled to report earnings on 2026-08-10.